BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 20379116)

  • 21. Low dose methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone with zalcitabine in patients with acquired immunodeficiency syndrome-related lymphoma. Effect on human immunodeficiency virus and serum interleukin-6 levels over time.
    Levine AM; Tulpule A; Espina B; Boswell W; Buckley J; Rasheed S; Stain S; Parker J; Nathwani B; Gill PS
    Cancer; 1996 Aug; 78(3):517-26. PubMed ID: 8697399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intensive sequential chemotherapy with hematopoietic growth factor support for non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus.
    Costello RT; Zerazhi H; Charbonnier A; de Colella JM; Alzieu C; Poizot-Martin I; Cohen R; Bardou VJ; Xerri L; Olive D; Nezri M; Lepeu G; Gastaut JA
    Cancer; 2004 Feb; 100(4):667-76. PubMed ID: 14770420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response.
    Levine AM; Tulpule A; Espina B; Sherrod A; Boswell WD; Lieberman RD; Nathwani BN; Welles L
    J Clin Oncol; 2004 Jul; 22(13):2662-70. PubMed ID: 15226333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Burkitt's lymphoma shortly after an acute HIV infection, treated with highly active retroviral treatment.
    Colebunders R; Dohmen S; Van de Velde A; Pelgrom J; Hermans P
    Acta Clin Belg; 2001; 56(5):321-2. PubMed ID: 11770227
    [No Abstract]   [Full Text] [Related]  

  • 25. Anti-cancer agents. Unique protocol looks promising for lymphoma.
    TreatmentUpdate; 2003; 15(4):5-7. PubMed ID: 17216853
    [No Abstract]   [Full Text] [Related]  

  • 26. Effects of recombinant granulocyte colony-stimulating factor (G-CSF) in patients treated with ProMACE-CytaBOM for HIV-related non-Hodgkin's lymphoma (NHL).
    Rossi G; Donisi A; Casari S; Re A; Stellini R; Cadeo G; Carosi G
    Haematologica; 1998 Apr; 83(4):317-22. PubMed ID: 9592981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Burkitt lymphomas failing dose-adjusted R-EPOCH (DA-R-EPOCH).
    Aurer I; Bašić-Kinda S; Radman I; Ilić I; Grah JJ
    Ann Hematol; 2014 Jan; 93(1):177-8. PubMed ID: 23636314
    [No Abstract]   [Full Text] [Related]  

  • 28. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494).
    Sparano JA; Lee S; Chen MG; Nazeer T; Einzig A; Ambinder RF; Henry DH; Manalo J; Li T; Von Roenn JH
    J Clin Oncol; 2004 Apr; 22(8):1491-500. PubMed ID: 15084622
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful treatment with autologous peripheral blood stem cell transplantation for acquired immunodeficiency syndrome (AIDS)-related malignant lymphoma.
    NAGAI Y; MORI M; INOUE D; KIMURA T; SHIMOJI S; TOGAMI K; TABATA S; MATSUSHITA A; NAGAI K; Imai Y; Takafuta T; Takahashi T
    Rinsho Ketsueki; 2009 Nov; 50(11):1641-6. PubMed ID: 20009441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.
    Romaguera JE; Fayad L; Rodriguez MA; Broglio KR; Hagemeister FB; Pro B; McLaughlin P; Younes A; Samaniego F; Goy A; Sarris AH; Dang NH; Wang M; Beasley V; Medeiros LJ; Katz RL; Gagneja H; Samuels BI; Smith TL; Cabanillas FF
    J Clin Oncol; 2005 Oct; 23(28):7013-23. PubMed ID: 16145068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current status of the treatment of HIV-associated lymphoma.
    Kaplan LD
    Clin Adv Hematol Oncol; 2004 Jan; 2(1):28-9. PubMed ID: 16163156
    [No Abstract]   [Full Text] [Related]  

  • 32. Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine.
    Inamdar KV; Romaguera JE; Drakos E; Knoblock RJ; Garcia M; Leventaki V; Medeiros LJ; Rassidakis GZ
    Cancer; 2009 Oct; 115(20):4727-36. PubMed ID: 19708031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary Burkitt's lymphoma of the ovary.
    Cyriac S; Srinivas L; Mahajan V; Sundersingh S; Sagar TG
    Afr J Paediatr Surg; 2010; 7(2):120-1. PubMed ID: 20431226
    [No Abstract]   [Full Text] [Related]  

  • 34. A 5-drug regimen maximizing the dose of cyclophosphamide is effective therapy for adult Burkitt or Burkitt-like lymphomas.
    Kujawski LA; Longo WL; Williams EC; Turman NJ; Brandt N; Mosher DF; Eickhoff JC; Kahl BS
    Cancer Invest; 2007 Mar; 25(2):87-93. PubMed ID: 17453819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV-related lymphoma treated with maintenance thalidomide.
    Larson ML; Enschede SH; Gregory SA
    Clin Adv Hematol Oncol; 2005 Mar; 3(3):231-4; discussion 234-5. PubMed ID: 16166993
    [No Abstract]   [Full Text] [Related]  

  • 36. [Early relapse of Burkitt's lymphoma with t(8;14) and t(14;18) after rituximab-combined CODOX-M and IVAC therapy].
    Fujishima N; Fujishima M; Inomata M; Yamanaka Y; Saitoh K; Kameoka Y; Yoshioka T; Saitoh H; Takahashi N; Hirokawa M; Sawada K
    Rinsho Ketsueki; 2007 Apr; 48(4):326-31. PubMed ID: 17515125
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology.
    Little RF; Pittaluga S; Grant N; Steinberg SM; Kavlick MF; Mitsuya H; Franchini G; Gutierrez M; Raffeld M; Jaffe ES; Shearer G; Yarchoan R; Wilson WH
    Blood; 2003 Jun; 101(12):4653-9. PubMed ID: 12609827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
    Wang M; Fayad L; Cabanillas F; Hagemeister F; McLaughlin P; Rodriguez MA; Kwak LW; Zhou Y; Kantarjian H; Romaguera J
    Cancer; 2008 Nov; 113(10):2734-41. PubMed ID: 18973182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose-intensified treatment of Burkitt lymphoma and B-cell lymphoma unclassifiable, (with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma) in young adults (<50 years): a comparison of two adapted BFM protocols.
    Tauro S; Cochrane L; Lauritzsen GF; Baker L; Delabie J; Roberts C; Mahendra P; Holte H
    Am J Hematol; 2010 Apr; 85(4):261-3. PubMed ID: 20201088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapy of HIV-associated lymphoma-recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNÄ), in cooperation with the German AIDS Society (DAIG).
    Hentrich M; Hoffmann C; Mosthaf F; Müller M; Siehl J; Wyen C; Hensel M; ;
    Ann Hematol; 2014 Jun; 93(6):913-21. PubMed ID: 24807241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.